Johnson & Johnson’s Darzalex is already on track to nab a second multiple myeloma nod in newly diagnosed patients in the U.S., but its journey with England’s cost watchdog hasn’t been so smooth.
Johnson & Johnson’s Darzalex is already on track to nab a second multiple myeloma nod in newly diagnosed patients in the U.S., but its journey with England’s cost watchdog hasn’t been so smooth.
My Smoldering Life 